Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13018958 | 0.90 | SYK (0.42) | CCR2BTKMAP3K12 | |
| SCHEMBL3779367 | 0.82 | CCR2 (0.41) | CCR2BTKMAP3K12FFAR4CCR5 | |
| SCHEMBL13806857 | 0.78 | PDE4A (0.39) | CCR5 | |
| SCHEMBL3782885 | 0.77 | CCR2 (0.36) | CCR2BTKALDH1A1MEN1USP2 | |
| SCHEMBL13806570 | 0.74 | CCR2 (0.36) | CCR2BTKMAP3K12 | |
| SCHEMBL1119803 | 0.73 | CCR2 (0.47) | CCR2CYP3A4 | |
| SCHEMBL3788239 | 0.72 | MAP3K12 (0.47) | MAP3K12RORC | |
| SCHEMBL3033156 | 0.70 | MAP3K12 (0.45) | CCR2MAP3K12CCR5 | |
| SCHEMBL20743116 | 0.70 | JAK2 (0.44) | MAP3K12RORCMEN1CYP3A4KMT2A | |
| SCHEMBL20743055 | 0.68 | MAP3K12 (0.44) | MAP3K12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| WO-2009076404-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE CHEMOKINE CCR2 RECEPTOR | EPIX DELAWARE, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | CCR2 1/4885BTK 1555/4885MAP3K12 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.